Skip to main content
October 6, 2016

The University of North Carolina at Chapel Hill will pursue treatments for specific cancer targets as a specialized member of the National Cancer Institute’s renewed Experimental Therapeutics, or NExT, program.

Because of its unique expertise, UNC has been designated a specialized center in the NCI’s Chemical Biology Consortium, the NExT program’s discovery engine. The university’s team is led by Stephen Frye, Ph.D., Fred Eshelman Distinguished Professor at the UNC Eshelman School of Pharmacy and director of the school’s Center for Integrative Chemical Biology and Drug Discovery. Frye is also a member of the UNC Lineberger Comprehensive Cancer Center and co-director of its molecular therapeutics program.  Read More…

Comments are closed.